PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K reporting that on May 5, 2026 its board approved resolutions allowing TD Securities (USA) LLC (TD Cowen), as sales agent, to sell the company’s common stock to one or more company affiliates through the company’s at-the-market (ATM) Equity Distribution Agreement dated February 19, 2026. The ATM permits sales of common stock having an aggregate offering price of up to $59,976,196. Co-Chairman Robert Duggan (beneficial owner of ~72% of outstanding shares as of March 31, 2026) and CEO/Co-Chairman Paul LaViolette said they are likely to purchase shares in the near term but made no binding commitments or specified amounts; any purchases would be at the prevailing market bid price or better.

Key Details

• ATM Sales Agreement date: February 19, 2026; sales agent: TD Securities (USA) LLC (TD Cowen).
• Aggregate ATM capacity: up to $59,976,196 of common stock.
• Board approval date permitting affiliate purchases through the ATM: May 5, 2026.
• Major insiders: Robert Duggan (~72% beneficial owner as of 3/31/2026) and CEO Paul LaViolette indicated likely near-term purchases but gave no firm commitments or quantities; purchases would be at market bid price or better.

Why It Matters
This filing matters because the company has an active mechanism to raise up to roughly $60 million by selling shares through an ATM program. Allowing affiliates (including major shareholders and the CEO) to buy through the ATM at market prices could affect how much new stock is absorbed by insiders versus the public, which in turn influences potential dilution and available float. Investors should note there are no firm commitments from insiders and that any future sales under the ATM would change the share count and could affect liquidity and share price.